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Abstract
Background: Since the precise mechanism for the pathogenesis of systemic lupus erythematosus (SLE) is unknown,
no targeted therapies in addition to immunosuppression are available so far. We recently demonstrated that
administration of the topoisomerase I (topo I) inhibitor irinotecan at extremely low concentrations reversed established
lupus nephritis in NZB/NZW mice. While profound immunosuppression was absent, we proposed changes in DNA
relaxation and anti-double-stranded (ds)DNA antibody binding as the underlying mechanism. To exclude that these
effects were restricted to NZB/NZW mice, irinotecan was used in a genetically different strain of lupus-prone mice.
Methods: MRL/lpr mice were treated with high- and low-dose irinotecan beginning at 8 weeks of age. Treatment was
repeated every fourth week. In vitro, DNA was relaxed by recombinant topo I, and altered anti-dsDNA antibody
binding was measured by enzyme-linked immunosorbent assay.
Results: Administration of both high- and low-dose irinotecan prevented proteinuria and prolonged survival in MRL/
lpr mice. Moreover, both concentrations of irinotecan significantly improved histopathology of the skin at 18 weeks of
age. While only high-dose irinotecan diminished the numbers of plasmablasts and double-negative T cells, no changes
in IgG-secreting cells or anti-dsDNA IgG were observed. In vitro, relaxation of DNA by topo I increased the binding of
anti-dsDNA IgG but not the binding of anti-dsDNA IgM derived from the plasma of MRL/lpr mice.
Conclusion: The beneficial effects of topo I inhibition in a second, genetically different strain of lupus-prone mice
strongly implicate irinotecan as a new therapeutic option for human SLE.
Keywords: Systemic lupus erythematosus (SLE), Lupus nephritis, Lupus-like skin lesions, Alternative treatment for SLE,
Inhibitors of topoisomerase I, DNA relaxation, Anti-dsDNA binding
Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease mainly affecting women of childbearing
age. It is estimated that, in the USA, up to 275,000 adult
women suffer from SLE [1]. The disease involves differ-
ent organs, but immune complex glomerulonephritis
most strikingly influences the course of SLE. Ten to
thirty percent of patients with lupus nephritis progress
to end-stage renal disease (ESRD) resulting in
hemodialysis or kidney transplantation [2]. Due to the
application of immunosuppressive drugs, the survival of
patients with lupus-associated glomerulonephritis in-
creased from a 5-year survival of 44 % in the 1950s to a
10-year survival of 88 % recently [3]. Despite these
advances in the treatment of SLE, the life expectancy of
patients with lupus and renal damage was recently
demonstrated to be 23.7 years shorter compared to the
general population [4]. Moreover, the incidence of ESRD
associated with lupus nephritis has not decreased over
the last years [5], indicating that current medication is
insufficient to treat lupus nephritis.
Unselective immunosuppressive drugs remain the
central strategy to control lupus nephritis. Medication
consists of an induction therapy with cyclophosphamide
and prednisolone or mycophenolate mofetil, followed by a
maintenance therapy with azathioprine or mycophenolate
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mofetil [6, 7]. Major side effects of this medication are
infections, and they bear the risk of malignancies where-
upon cyclophosphamide also causes amenorrhea [8–10].
Furthermore, none of the newly developed biological
agents such as rituximab, ocrelizumab, atacicept, or abata-
cept demonstrated beneficial effects in patients with active
lupus nephritis [11–15]. Two other biologicals reached
statistical significance for the improvement of moderate to
severe forms of SLE. However, the benefit of belimumab
and tabalumab were modest [16, 17], the “number needed
to treat” was high, and other phase III studies hardly
reproduced the first results [18, 19].
The precise mechanism for the pathogenesis of SLE is
unknown. Therefore, no targeted therapies beside
immunosuppression exist so far. However, a potentially
targeted therapy for SLE was suggested by a new finding
from our group which was generated by serendipity. We
demonstrated that the topoisomerase I (topo I) inhibitor
irinotecan efficiently suppressed murine lupus nephritis
in New Zealand Black/New Zealand White (NZB/NZW)
mice [20–22]. It was the first time that topo I was linked
to the treatment of lupus nephritis.
Topo I is ubiquitously expressed and highly conserved
[23, 24]. Its major function is the relaxation of super-
coiled DNA in order to release torsional stress from
DNA occurring during replication and transcription. To
mediate DNA relaxation, topo I binds to DNA and
cleaves one DNA strand, subsequently allowing the
rotation of the cleaved strand around the other in a con-
trolled reaction [25]. Afterwards, the nicked strand is re-
ligated by topo I restoring intact double-stranded
(ds)DNA in a relaxed state.
Inhibitors of topo I stabilize a normally very transient
catalytic intermediate in which topo I is bound to one
strand of the DNA, known as the topo I cleavable com-
plex. When the cleavable complex is stalled by topo I
inhibitors, re-ligation of the DNA is impossible [26]. The
consequence of prevented re-ligation may vary; in prolif-
erating cells, the stalled topo I cleavable complex can
collide with replication forks leading to unrepairable
DNA double strand breaks and apoptosis [27, 28]. For
this reason, topo I inhibitors, like camptothecin and its
synthetic derivative irinotecan, are widely used as an-
ticancer drugs for several types of tumors [29]. In
non-dividing cells, the treatment with topo I inhibi-
tors results in the production of single-stranded
(ss)DNA breaks reducing the replication capacity of a
cell, although this is not lethal [26]. In addition to
the induction of ssDNA and dsDNA breaks, topo I
inhibitors were shown at least in vitro to inhibit DNA
relaxation [30, 31].
In our first experiments, we applied concentrations of
irinotecan that were similar to those used for chemo-
therapy in humans [20]. Although irinotecan reversed
established lupus nephritis, there have been some con-
cerns about using yet another chemotherapeutic for the
treatment of SLE in predominantly young women. How-
ever, subsequent experiments by our group demon-
strated that much lower dosages were still efficient to
suppress SLE. We ended up with a dose more than 50
times lower than the dose used for chemotherapy in
humans, which still enabled the successful treatment of
established lupus nephritis in NZB/NZW mice [21].
These extremely low concentrations guided us to the hy-
pothesis that inhibition of topo I might be a targeted
therapy for SLE. While a profound immunosuppression
was ruled out [20–22], we hypothesized in the beginning
that induction of ssDNA breaks as a consequence of
topo I inhibition is the underlying mechanism [32].
However, later we found that topo I alone increased
binding of anti-dsDNA antibodies [21, 22] supposing
that DNA relaxation is critically involved in the patho-
genesis of SLE.
All previous experiments using irinotecan for the
treatment of SLE were performed in NZB/NZW mice.
To provide more evidence for first clinical trials treating
human SLE we had to rule out that the demonstrated
effects of irinotecan are restricted to NZB/NZW mice.
We therefore introduced the MRL/lpr mouse model
which is characterized by a fast and severe disease pro-
gression involving fatal glomerulonephritis, vasculitis,
skin lesions, and massive lymphadenopathy [33, 34]. In
these mice, we tested whether irinotecan has similar
beneficial effects on lupus-like disease as shown before
in NZB/NZW mice.
Methods
Mice
Female MRL/lpr and MRL/MpJ mice, aged 6 weeks,
were purchased from The Jackson Laboratory and kept
in isolated ventilated cages. Immediately after arrival,
mice were randomly assigned to the respective groups
(five animals per cage).
Animal study: treatment of MRL/lpr with irinotecan
At 8 weeks of age, MRL/lpr mice were injected intraper-
itoneally with saline, or 1 or 25 mg/kg irinotecan
(Campto®; Pfizer). MRL/MpJ mice treated with saline
were used as controls. The volume of each injection was
10 ml/kg. Mice were treated three times per week. The
treatment cycle was repeated after 4 weeks. Beginning at
an age of 7 weeks, mice were monitored for proteinuria
and body weight once a week. Proteinuria was measured
with Albustix (Siemens Healthcare Diagnostics) and
analyzed semiquantitively as grade 0 (negative), grade 1+
(≥30 mg/dl), grade 2+ (≥100 mg/dl), grade 3+ (≥300 mg/
dl), and grade 4+ (≥2000 mg/dl) according to the manu-
facturer’s recommendations. The onset of proteinuria
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was defined as two instances of grade 4+ proteinuria
occurring 1 week apart. Moreover, skin in the dorsal
neck region, from the snout, and from the ears was
scored individually in a semiquantitative manner using a
score system from 0, for no lesion, to 2, for severe mani-
festation. Mice were killed when disease became severe
(proteinuria grade 4+ and a body weight loss of ≥25 %
from the onset of disease) and/or the total skin score
was ≥4. The experiment was terminated when mice
reached 37 weeks of age.
Histopathology of kidney and skin sections
Kidney and skin obtained from the dorsal regions were
fixed overnight in 4 % paraformaldehyde and embedded
in paraffin. Standard protocols were used for hematoxylin
and eosin, periodic acid-Schiff, and methenamine-silver
staining.
For cryosections, tissue was immediately placed in OCT,
snap frozen in liquid nitrogen and stored at –80 °C.
Sections (6-μm thick) were fixed in acetone for 10 min
before incubation with Alexa Fluor 488-conjugated goat
anti-mouse IgG (H + L chain specific; Invitrogen). The
kidney score of glomerulonephritis was assessed by an
independent pathologist who was blinded to the groups
using the International Society of Nephrology/Renal
Pathology Society 2004 classification [35]. Skin was graded
semiquantitatively according to Mizui et al. [36]; briefly,
grade of acanthosis (none (0) to markedly thickened
dermis (2)), hyperkeratosis (none (0) to strongly enhanced
keratin (3)), fibrosis (normal (0) to markedly thickened
dermal collagen (3)), inflammation (sparse (0) to substan-
tial lymphocytic infiltrates (3)), and ulcer (absent (0) or
present (1)).
Isolation of splenocytes and lung cells
Spleens were harvested from mice and immediately
transferred into ice-cold phosphate-buffered saline
(PBS), and smashed on a sterile grid with a pestle. Cells
were incubated in red blood cell lysis buffer for 2 min
on ice, debris was allowed to settle out by centrifugation
at 65 g for 2 min at 4 °C, and cells were re-suspended in
RPMI 1640 supplemented with 10 % fetal calf serum
(FCS). Cell viability was checked by trypan blue
exclusion.
The left lobe of the lung was minced to small pieces
and digested in RPMI 1640 without supplement contain-
ing 100 μg/ml Liberase (Roche) for 90 min at 37 °C and
5 % CO2. Digestion was stopped by adding fetal bovine
serum (Gibco) to a final concentration of 10 %. Cells
were passed through a 40-μm cell strainer, incubated in
red blood cell lysis buffer for 2 min on ice and resus-
pended in RPMI 1640 media for cell counting and
further analysis.
Flow cytometry
Unspecific binding was blocked by incubating cells with
Fc receptor-blocking monoclonal antibody (clone 2.4G2;
BD Biosciences) for 10 min. Cells were then stained with
the following antibodies specifically binding: CD3-PerCP/
Cy5.5 (145-2C11; BioLegend), CD4-BV785 (RM4-5;
BioLegend), CD8-BV421 (53-6.7; BioLegend), B220/CD45R-
APC-Cy7 (RA3-6B2; BioLegend), CD138-BV605 (281-2;
BioLegend), CD69-PE (H1.2 F3; BioLegend), and PD-1-PE-
Cy7 (29 F.1A12; BioLegend). Dead cells were excluded by
ZombieGreen™ (BioLegend) staining, and doublets by scatter
analysis. Cells were measured on a LSRII flow cytometer
(BD) and analyzed by FlowJo software. In most samples, a
minimum of 1 × 105 events were measured.
Enzyme-linked immunosorbent spot (ELISpot) assay
Serial dilutions of splenocytes in RPMI 1640 supple-
mented with 10 % FCS were added to 96-well Multiscreen
HTS Immobilon-P flat-bottomed plates (Millipore) pre-
coated with goat anti-mouse IgG (Fc specific; Sigma-
Aldrich) or goat anti-mouse IgM antibodies (BioLegend).
After 4 h at 37 °C, plates were washed and incubated with
alkaline phosphatase-conjugated anti-mouse IgG or
alkaline phosphate-conjugated anti-mouse IgM (H + L
chain specific, SouthernBiotech) for 1 h. Spots were devel-
oped with BCIP/nitroblue tetrazolium plus substrate
(Sigma-Aldrich) and counted with an ELISpot reader
(Autoimmun Diagnostika).
Enzyme-linked immunosorbent assay (ELISA)
Ninety-six-well Nunc MaxiSorp plates were coated with
5 μg/ml goat anti-mouse IgG (Sigma) or anti-mouse IgM
(SouthernBiotech) overnight at 4 °C. Plates were blocked
with 1 % bovine serum albumin (BSA) in PBS for 1 h at
37 °C followed by incubation with diluted plasma samples
for 1 h at 37 °C. Subsequently, plates were incubated with
alkaline phosphatase-conjugated goat anti-mouse IgG or
anti-mouse IgM (SouthernBiotech) for 1 h at 37 °C and
developed with p-nitrophenyl phosphate (Sigma-Aldrich).
Optical density was measured at 405 nm with a reference
filter at 490 nm. Sample concentrations were calculated
using a standard curve of purified mouse IgG (Sigma) and
IgM (SouthernBiotech).
To determine anti-dsDNA antibodies, calf thymus DNA
(Invitrogen) was passed through a Millex-HA 0.45-mm
filter (Millipore) to remove any ssDNA fragments. Maxi-
sorp plates were half-coated with 100 mg/ml calf thymus
DNA in PBS overnight at 4 °C. Plates were blocked with
PBS containing 1 % BSA for 1 h at 37 °C. Diluted plasma
samples were incubated at 37 °C for 1 h. Bound anti-
dsDNA autoantibodies were detected as described above
for total IgG or IgM ELISA, respectively.
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DNA modification
Calf thymus DNA (50 mg/ml) was incubated with 4 μg/ml
recombinant human topo I (Creative Biomart) in 50 mM
Tris HCl (pH 7.5), 50 mM KCl, 2 mM dithiothreitol
(DTT), and 1 mM EDTA for 30 min at 37 °C. Then, 30 ml
of sample per well was used for coating a 384-well Nunc
Maxi-Sorp plate overnight at 4 °C. Plates were blocked
with PBS containing 1 % casein (Pierce) for 1 h at 37 °C.
Next, depending on the experiment, diluted plasma
samples from MRL/lpr mice were added to the plates for
1 h at 37 °C. Bound antibodies were detected as described
above for anti-dsDNA IgG and IgM ELISA.
Statistical analysis
Data were analyzed using either one-way or two-way ana-
lysis of variance (ANOVA) followed by Bonferroni’s post-
hoc test, respectively. Some data were assessed by paired t
test. Survival data were analyzed using the Mantel-Cox log
rank test. For all tests, the software GraphPad Prism version
6.0 was used. P values <0.05 were considered as significant.
Results
Irinotecan attenuated symptoms of lupus-like disease and
prolonged survival in MRL/lpr mice
MRL/lpr mice possess a rapid and severe form of lupus-
like disease. For clinical monitoring, the involvement of
the kidneys with proteinuria and the involvement of skin
with alopecia, pruritus, and necrotic lesions are import-
ant. Both organ contributions influence the survival of
these mice, in contrast to the NZB/NZW model prefera-
bly showing renal manifestations.
Mice were treated with high- and low-dose irinotecan
from 8 weeks of age. The dosages for high- and low-dose
irinotecan were obtained from previous experiments in
NZB/NZW mice. As described before, low-dose irinote-
can corresponds to a dose which is 50 times lower than
the dose used for chemotherapy in humans [20–22].
Saline-treated MRL/lpr mice started to develop severe
proteinuria from 12 weeks of age. At 21 weeks of age,
grade 4+ proteinuria measured at two consecutive weeks
affected 90 % of saline-treated animals. In contrast, both
high- and low-dose irinotecan significantly prevented the
onset of proteinuria from 16 weeks of age (Fig. 1a). Look-
ing at the clinically determined skin score, only high-dose
but not low-dose irinotecan suppressed the onset of
detrimental skin lesions (Fig. 1b). Improvement of the
skin score mediated by high-dose irinotecan was
statistically significant until 27 weeks of age. Notably,
the graph in Fig. 1b implies that MRL/lpr mice
treated with low-dose irinotecan developed more
severe lupus-like skin lesions than saline-treated
animals. However, since saline-treated MRL/lpr mice
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Fig. 1 Suppression of SLE by irinotecan in MRL/lpr mice. Beginning at 8 weeks of age, MRL/lpr mice (n = 10 per group) were treated with saline,
or 25 mg/kg or 1 mg/kg irinotecan. Treatment was performed three times a week and repeated every fourth week. a Frequency of proteinuria
measured as grade 4+ at two consecutive weeks. b Skin score semiquantitatively assessed at the snout, ears, and dorsal region. Percent survival,
showing animals sacrificed c due to lupus nephritis and excluding mice sacrificed due to skin lesions (n = 8 for saline, n = 10 for 25 mg/kg
irinotecan, and n = 7 for 1 mg/kg irinotecan) or d including both lupus nephritis and skin lesions as sacrifice criteria (n = 10 for each group).
Values represent the mean ± SEM. *P < 0.05, **P < 0.01, versus saline-treated MRL/lpr mice by two-way analysis of variance corrected by
Bonferroni’s multiple comparisons test (a and b) or Mantel-Cox log rank test (c and d)
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showed a rapidly progressing glomerulonephritis in
contrast to irinotecan-treated animals, they had to be
sacrificed before they could reach higher levels of skin
lesions.
Excluding animals that were sacrificed due to the skin
score, both high- and low-dose irinotecan demonstrated
a significantly improved survival at 20 weeks of age
(Fig. 1c). When including all animals, only MRL/lpr
mice treated with high-dose irinotecan demonstrated an
increased survival of 80 % compared to 0 % of saline-
treated mice and 10 % of animals treated with low-dose
irinotecan at 37 weeks of age (Fig. 1d).
For functional measurements, other groups of MRL/lpr
mice were sacrificed at 18 weeks of age. MRL/MpJ mice
were used as controls. Determination of the kidney score
revealed an amelioration of glomerulonephritis for both
irinotecan concentrations; however, only high-dose irino-
tecan showed a significant improvement (Fig. 2a). The
skin score at 18 weeks of age assessed on paraffin sections
by a blinded pathologist demonstrated a suppression of
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manner. Bars show the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, versus saline-treated MRL/lpr mice by one-way analysis of variance corrected by
Bonferroni’s post hoc test. Clinically determined proteinuria (a) and skin score (b) of these animals are shown from 17 weeks of age
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lupus-like skin lesions for both irinotecan-treated groups
(Fig. 2b). Remarkably, when looking at the clinically deter-
mined parameters in Figs. 1 and 2, we noticed some differ-
ences between the groups of mice at 17 weeks of age: living
saline-treated animals in Fig. 1 showed a proteinuria of 2.6
(mean, data not shown) while saline-treated mice in Fig. 2
presented a proteinuria of 1.5 (mean) at the same age.
Immunomodulatory effects of irinotecan treatment in
MRL/lpr mice
MRL/lpr mice bear a mutation in the Fas receptor
(CD95). As a consequence, autoreactive immune cells
fail to undergo apoptosis and accumulate in lymphoid
structures [37]. We therefore examined how treatment
with irinotecan influenced the immune system of MRL/
lpr mice. Analysis of the spleen from mice sacrificed at
18 weeks of age described above revealed clear signs of
splenomegaly in saline-treated MRL/lpr mice compared
to MRL/MpJ mice. This effect was significantly reduced
in MRL/lpr mice treated with high-dose irinotecan,
whereas low-dose irinotecan had no influence on
splenomegaly (Fig. 3a). In addition to splenomegaly, a
massive proliferation of CD4/CD8 double-negative (DN)
T cells is characteristic for MRL/lpr mice. These cells
seem to be unresponsive to antigen-receptor stimulation
and have no T-helper activity [38, 39]. Determination of
DN T cells identified as CD3+B220+CD4–CD8– cells
demonstrated a significant reduction of this cell popula-
tion in mice treated with high-dose irinotecan. No effect
was seen for low-dose irinotecan compared to saline-
treated MRL/lpr mice (Fig. 3b).
B-cell numbers identified as CD3–B220+CD138– cells
remained unchanged in both irinotecan-treated groups
(Fig. 3c). By contrast, the expression of CD69 on B cells
and the numbers of plasmablasts (CD3–B220+CD138int)
were significantly decreased in MRL/lpr mice treated
with high-dose irinotecan. For plasma cells (CD3–
B220–CD138+), no significant effect of either high-
dose or low-dose irinotecan compared to saline was
observed (Fig. 3c).
Next, we analyzed the numbers of antibody-secreting
cells in the spleen. Surprisingly, increased numbers of
IgG- and IgM-secreting cells in MRL/lpr mice were
not affected by high- or low-dose irinotecan (Fig. 4a).
In line with that, no changes in the plasma levels of
total IgG and IgM were detected (Fig. 4b). Measure-
ment of anti-dsDNA IgGs showed increased plasma
levels in saline-treated MRL/lpr mice which were not
significantly reduced in both irinotecan-treated groups
(Fig. 4c, left). Unexpectedly, when analyzing anti-
dsDNA IgM we found diminished, albeit not signifi-
cantly, plasma levels in MRL/lpr mice treated with
low-dose irinotecan while there was no reduction of
anti-dsDNA IgM in MRL/lpr mice treated with high-
dose irinotecan (Fig. 4c, right).
High-dose irinotecan decreased the number of DN T cells
infiltrating the lung
In addition to inflammatory processes in the kidneys
and skin, MRL/lpr mice also exhibit pulmonary auto-
immune disease which is caused by infiltration of
mononuclear cells [40]. Analysis of different immune
cell subsets in the lungs of 18-week-old MRL/lpr mice
revealed a significant reduction of the number of CD3+
cells and DN T cells in the group treated with high-dose
irinotecan (Fig. 5a). Moreover, there was some reduction
in IgG-secreting lung cells in both irinotecan-treated
groups; however, the difference did not reach statistical
significance (Fig. 5b).
Increased binding of anti-dsDNA antibodies to DNA
modified by topo I was restricted to the IgG isotype
Previous data from our group established a link between
the extent of DNA relaxation and anti-dsDNA antibody
binding. We demonstrated that anti-dsDNA antibody
binding to DNA relaxed by recombinant topo I was
clearly enhanced. This effect was shown for different
types of DNA and for anti-dsDNA antibodies from
different sources [21, 22]. To clarify whether this effect
can be also applied to anti-dsDNA antibodies derived
from MRL/lpr mice, we modified calf thymus DNA with
recombinant topo I and assessed anti-dsDNA IgG
binding by ELISA. Compared to BSA, DNA relaxed by
topo I revealed a significantly increased binding of anti-
dsDNA IgG from the plasma of MRL/lpr mice (Fig. 6a),
in line with our previous observations. For the first time
we also determined the binding of anti-dsDNA IgM to
DNA modified by topo I. Applying the same conditions
(See figure on previous page.)
Fig. 3 Prevention of splenomegaly by high-dose irinotecan (Irino). Spleens from 18 week-old MRL/lpr mice treated with saline (n = 7), 25 mg/kg
irinotecan (n = 6), or 1 mg/kg irinotecan (n = 6) were analyzed by flow cytometry. MRL/MpJ mice treated with saline (n = 7) were used as controls
(Ctrl). a Representative image of the spleen from each treatment group (left) and the spleen weights (right). b Representative bivariate contour
plots from each treatment group showing the subpopulation of T cells double negative for CD4 and CD8 and positive for CD3 and B220 (DN T
cells). Cells were gated for live, singlets, and negative for CD4 and CD8 expression. (Right) Total number of splenic DN T cells. c (Top left) Numbers
of CD3–B220+CD138– B cells and (top right) the expression of CD69. (Bottom left) Numbers of CD3–B220+CD138+ plasmablasts and (bottom right)
CD3–B220–CD138+ plasma cells. Each symbol represents an individual mouse; bars show mean ± SEM.*P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001, versus saline-treated MRL/lpr mice by one-way analysis of variance with Bonferroni post hoc test
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as described for anti-dsDNA IgG binding, we found that
topo I-mediated DNA relaxation did not increase the
binding of anti-dsDNA IgM derived from the plasma of
MRL/lpr mice (Fig. 6b). Therefore, increased anti-
dsDNA antibody binding following DNA relaxation
seems to be restricted to anti-dsDNA IgG, which was an
unexpected finding.
Discussion
Five years ago, our group reported for the first time that
the topo I inhibitor irinotecan is able to suppress lupus
nephritis in NZB/NZW mice [20], a finding that was
based on serendipity obtained from cancer research ex-
periments. In those experiments, immunocompetent
mice were treated with a human protein either alone or
in combination with irinotecan. During the second cycle
of treatment, all mice from the group treated with the
protein alone died within 3 days whereas all mice treated
with the protein in combination with irinotecan
survived. In the review of these unexpected results we
speculated about the occurrence of some form of fatal
hypersensitivity reaction and a protective effect of irino-
tecan against this. Based on this hypothesis we intro-
duced a mouse model for anaphylaxis in terms of fast
hypersensitivity reaction. However, irinotecan failed to
delay the onset of anaphylactic shock (unpublished
results). We next checked whether protection from de-
layed hypersensitivity reactions was involved and estab-
lished two mouse models of spontaneous autoimmune
disease: diabetes in NOD mice and SLE in NZB/NZW.
While irinotecan had no effect on the development of
autoimmune diabetes (unpublished data), application of
the topo I inhibitor almost completely prevented the on-
set of lupus nephritis. Encouraged by this finding we also
examined whether irinotecan ameliorates the course of
two other autoimmune diseases, multiple sclerosis and
systemic sclerosis. Both attempts failed (unpublished
results) providing evidence that inhibition of topoisom-
erase I is a specific treatment for SLE. This suggestion
was supported by further experiments showing that ex-
tremely low concentrations of irinotecan still suppressed
lupus nephritis and prolonged survival in NZB/NZW
mice [21]. Final support for the potential use of irinotecan
as a novel treatment strategy for SLE patients comes from
our findings showing that irinotecan, even at a low dose,
does not result in profound immunosuppression [20–22].
Instead, we presented evidence that alterations in DNA
relaxation and subsequent changes in binding of anti-
dsDNA antibodies may account for irinotecan-mediated
effects in SLE [21, 22].
Are these data sufficient enough to legitimize first
clinical trials treating lupus patients with irinotecan? Yes,
we think so. However, to provide additional support in
favor of clinical testing of irinotecan in human SLE, we
introduced the MRL/lpr mouse model which is genetically
different from NZB/NZW [41]. MRL/lpr mice were
treated with either high-dose or low-dose irinotecan. As a
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SEM. *P < 0.05, **P < 0.01, ***P < 0.001, versus saline-treated MRL/lpr
mice by one-way analysis of variance with Bonferroni post hoc test
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result, high-dose irinotecan clearly suppressed the devel-
opment of lupus-associated glomerulonephritis and pre-
vented the onset of skin lesions. When applying low-dose
irinotecan to MRL/lpr mice, the results were more
difficult to interpret. Undoubtedly, until week 20, low-
dose irinotecan almost completely inhibited the onset of
proteinuria, a time point when most of the MRL/lpr mice-
utilizing studies have finished [42–45]. Skin lesions were
prevented by low-dose irinotecan at least until week 18,
which was confirmed through histopathology assessed by
a blinded pathologist. After week 18, an increasing
number of mice from the group treated with low-dose
irinotecan had to be sacrificed due to a skin score ≥4. The
remaining mice of this group were suppressed for
proteinuria, suggesting that low-dose irinotecan was more
efficient at inhibiting lupus nephritis than skin lesions.
However, it is very likely that intermediate dosages of iri-
notecan exist that are considerably lower than the doses
used for chemotherapy, but which are still sufficient to
suppress both lupus nephritis and skin lesions in MRL/lpr
mice. This needs to be clarified in upcoming experiments.
Further investigation is also warranted for the finding that
topo I-mediated DNA relaxation increased binding of anti-
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dsDNA IgG but not binding of anti-dsDNA IgM. Notably,
anti-dsDNA IgM is known to have a protective function in
SLE [46–49]. However, our previous results showing that
DNA relaxation and anti-dsDNA IgG binding can be inhib-
ited by topo I inhibitors explain how irinotecan executes its
protective function in SLE. Without the use of a topo I
inhibitor, circulating DNA might be relaxed allowing in-
creased binding of anti-dsDNA IgG followed by inflamma-
tory disease. In contrast, when applying a topo I inhibitor,
circulating DNA might be less relaxed and, subsequently,
binding of anti-dsDNA IgG will be reduced. Then, assum-
ing that binding of anti-dsDNA IgM is independent of
DNA relaxation, more anti-dsDNA IgM with its lupus-
protective function would be able to bind to circulating
DNA. However, such a mechanism is very speculative thus
far and needs to be preferentially shown in vivo.
Summarizing our results, inhibition of topo I is highly
proficient at suppressing lupus nephritis and other symp-
toms of lupus-like disease in two different mouse models
of spontaneous SLE. Although the mechanism is not fully
understood yet, it seems that topo I inhibition represents a
specific and targeted therapy for SLE beyond immunosup-
pression. Therefore, first clinical trials applying low-dose
irinotecan to human SLE patients are urgently required.
Conclusions
The topo I inhibitor irinotecan suppressed both lupus
nephritis and lupus-like skin lesions in MRL/lpr mice.
Immunosuppression was not significantly involved in
irinotecan-mediated suppression of lupus-like disease in
MRL/lpr mice. As an alternative mechanism for irinotecan-
mediated effects on lupus-like disease, our data propose
altered binding of pathogenic anti-dsDNA IgG as a result
of changes in DNA relaxation.
In view of the highly conserved nature of topo I, and
considering the application of extremely low dosages of
the topo I inhibitor as well as the lack of immunosup-
pression, inhibition of topo I might be developed as the
first targeted therapy for human SLE.
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